Identification, epidemiological relatedness, and biofilm formation of clinical Chryseobacterium indologenes isolates from central Taiwan. 2015

Yi-Cheng Chang, and Hsueh-Hsia Lo, and Hsiu-Ying Hsieh, and Shan-Min Chang
Department of Internal Medicine, Fongyuan Hospital, Taichung, Taiwan.

BACKGROUND The clinical impact of Chryseobacterium indologenes infection is increasing; nevertheless, most studies had been conducted in northern Taiwan, but rarely in central Taiwan. METHODS Using 16S rRNA gene sequencing, 34 isolates of C. indologenes were identified at the Central Region Hospital Alliance between 2007 and 2011. Vitek 2 and matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (MALDI-TOF MS) methods were compared for the feasibility to identify this bacterium. Drug susceptibility test, biofilm formation, and pulsed-field gel electrophoresis (PFGE) were also performed. RESULTS All isolates were collected from hospitalized patients with an average age of 70.8 ± 18.5 years. The most prevalent sample was urine (50.0%), followed by sputum (32.4%). The accuracy rate of species-level identification reached 94.1% using the Vitek 2 method and 85.3% using the MALDI-TOF MS method. All of the isolates were resistant to gentamicin, amikacin, ceftriaxone, chloramphenicol, colistin, and imipenem, but completely susceptible to minocycline. While analyzing biofilm-forming ability, 38.2% (13/34) of C. indologenes isolates displayed a positive phenotype using the Luria-Bertani (LB) medium. However, 80.0% (4/5) of invasive isolates were biofilm producers. Based on PFGE analysis, several clusters were found, and the possible intrahospital spread of this bacterium in this area could not be excluded. CONCLUSIONS Both Vitek 2 and MALDI-TOF MS methods showed good ability in the determination of C. indologenes. Among the examined drugs, minocycline was the most potent one. As many as 38.2% C. indologenes isolates showed biofilm-forming ability. PFGE analyses revealed the possible intrahospital transmission of this bacterium in central Taiwan.

UI MeSH Term Description Entries
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004269 DNA, Bacterial Deoxyribonucleic acid that makes up the genetic material of bacteria. Bacterial DNA
D004275 DNA, Ribosomal DNA sequences encoding RIBOSOMAL RNA and the segments of DNA separating the individual ribosomal RNA genes, referred to as RIBOSOMAL SPACER DNA. Ribosomal DNA,rDNA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

Yi-Cheng Chang, and Hsueh-Hsia Lo, and Hsiu-Ying Hsieh, and Shan-Min Chang
December 2013, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi,
Yi-Cheng Chang, and Hsueh-Hsia Lo, and Hsiu-Ying Hsieh, and Shan-Min Chang
August 1997, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
Yi-Cheng Chang, and Hsueh-Hsia Lo, and Hsiu-Ying Hsieh, and Shan-Min Chang
December 2010, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi,
Yi-Cheng Chang, and Hsueh-Hsia Lo, and Hsiu-Ying Hsieh, and Shan-Min Chang
January 2014, Indian journal of medical microbiology,
Yi-Cheng Chang, and Hsueh-Hsia Lo, and Hsiu-Ying Hsieh, and Shan-Min Chang
April 2021, Annals of translational medicine,
Yi-Cheng Chang, and Hsueh-Hsia Lo, and Hsiu-Ying Hsieh, and Shan-Min Chang
December 2000, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi,
Yi-Cheng Chang, and Hsueh-Hsia Lo, and Hsiu-Ying Hsieh, and Shan-Min Chang
March 2013, Journal of applied microbiology,
Yi-Cheng Chang, and Hsueh-Hsia Lo, and Hsiu-Ying Hsieh, and Shan-Min Chang
August 2007, Antimicrobial agents and chemotherapy,
Yi-Cheng Chang, and Hsueh-Hsia Lo, and Hsiu-Ying Hsieh, and Shan-Min Chang
December 1997, Journal of clinical microbiology,
Yi-Cheng Chang, and Hsueh-Hsia Lo, and Hsiu-Ying Hsieh, and Shan-Min Chang
February 2014, Infection,
Copied contents to your clipboard!